Takeshi Okamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takeshi Okamoto has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
Katsuyuki Fukuda
Department of Gastroenterology, St. Luke’s International Hospital
35 shared publications- Naoki Sasahira
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
27 shared publications - Tsuyoshi Takeda
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
25 shared publications - Takashi Sasaki
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
24 shared publications - Masato Ozaka
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
23 shared publications - Takafumi Mie
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
22 shared publications
Latest Publications
- Open Access
- 8 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8711
Comparison of Reintervention Outcomes After Endoscopic Ultrasound-Guided Hepaticogastrostomy According to the Type of Initial Stent
Background/Objectives: The impact of initial stent type on endoscopic reintervention after endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) remains unclear. Methods: We retrospectively evaluated patients with malignant biliary obstruction who developed recurrent biliary obstruction (RBO) after EUS-HGS and underwent reintervention through the endosonographically created route (ESCR). Outcomes were compared according to initial stent type (plastic stent [PS] or self-expandable metallic stent [SEMS]). The association between initial stent type and time to RBO (TRBO) after definitive biliary drainage was assessed using Cox regression and Fine–Gray regression. Results: Of 170 patients who underwent EUS-HGS, 69 were included (PS, n = 23; SEMS, n = 46). The initial reintervention procedure was technically successful in 100% and 95.7% of patients, respectively (p = 0.55). Definitive biliary drainage was technically successful in all 69 patients, while clinical success was achieved in 62 (89.9%). No procedure-related adverse events were observed. Among patients with clinical success, median TRBO was 160 and 140 days in the PS and SEMS groups, respectively. Initial SEMS placement was not significantly associated with TRBO (adjusted hazard ratio, 1.32; 95% confidence interval [CI], 0.55–3.13) or the cumulative incidence of RBO (adjusted subdistribution hazard ratio, 1.67; 95% CI, 0.70–3.97). Conclusions: Endoscopic reintervention through the ESCR was technically feasible after both initial PS and SEMS placement. Initial stent type was not significantly associated with subsequent RBO, although the findings should be interpreted cautiously because of potential temporal confounding and the limited sample size.
- 8 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8711
Open AccessComparison of Reintervention Outcomes After Endoscopic Ultrasound-Guided Hepaticogastrostomy According to the Type of Initial Stent
Background/Objectives: The impact of initial stent type on endoscopic reintervention after endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) remains unclear. Methods: We retrospectively evaluated patients with malignant biliary obstruction who developed recurrent biliary obstruction (RBO) after EUS-HGS and underwent reintervention through the endosonographically created route (ESCR). Outcomes were compared according to initial stent type (plastic stent [PS] or self-expandable metallic stent [SEMS]). The association between initial stent type and time to RBO (TRBO) after definitive biliary drainage was assessed using Cox regression and Fine–Gray regression. Results: Of 170 patients who underwent EUS-HGS, 69 were included (PS, n = 23; SEMS, n = 46). The initial reintervention procedure was technically successful in 100% and 95.7% of patients, respectively (p = 0.55). Definitive biliary drainage was technically successful in all 69 patients, while clinical success was achieved in 62 (89.9%). No procedure-related adverse events were observed. Among patients with clinical success, median TRBO was 160 and 140 days in the PS and SEMS groups, respectively. Initial SEMS placement was not significantly associated with TRBO (adjusted hazard ratio, 1.32; 95% confidence interval [CI], 0.55–3.13) or the cumulative incidence of RBO (adjusted subdistribution hazard ratio, 1.67; 95% CI, 0.70–3.97). Conclusions: Endoscopic reintervention through the ESCR was technically feasible after both initial PS and SEMS placement. Initial stent type was not significantly associated with subsequent RBO, although the findings should be interpreted cautiously because of potential temporal confounding and the limited sample size.
- Open Access
Comparison of Two Partially Covered Metal Stents for Endoscopic Ultrasound‐guided Hepaticogastrostomy: A Multi‐Center Retrospective Study
Objectives: Endoscopic ultrasound‐guided hepaticogastrostomy (EUS‐HGS) is an alternative biliary drainage method after failed endoscopic retrograde cholangiopancreatography. Nevertheless, it is associated with adverse events (AEs), including peritonitis and stent migration. The influence of metallic stent (MS) design characteristics, including axial force (AF), on the safety and efficacy of EUS‐HGS remains unclear. Methods: This multicenter retrospective study included patients with unresectable malignant biliary obstruction who underwent EUS‐HGS using either a high‐AF MS (Niti‐S biliary S‐type) or a low‐AF MS (EGIS biliary) between January 2019 and December 2022. Propensity score matching was performed in a 1:2 ratio. Outcomes included clinical success, early and late non‐recurrent biliary obstruction (non‐RBO) AEs, RBO, time to RBO (TRBO), and overall survival (OS). Results: After matching, 27 patients in the high‐AF group and 54 in the low‐AF group were analyzed. Clinical success, RBO rate, TRBO, OS, and late non‐RBO AE rates were similar between groups. However, early non‐RBO AEs were more frequent in the high‐AF group (37% vs. 13%, p = 0.02). Conclusions: Of the two partially covered MSs evaluated, the EGIS biliary stent demonstrated fewer early non‐RBO AEs after EUS‐HGS.
Open AccessComparison of Two Partially Covered Metal Stents for Endoscopic Ultrasound‐guided Hepaticogastrostomy: A Multi‐Center Retrospective Study
Objectives: Endoscopic ultrasound‐guided hepaticogastrostomy (EUS‐HGS) is an alternative biliary drainage method after failed endoscopic retrograde cholangiopancreatography. Nevertheless, it is associated with adverse events (AEs), including peritonitis and stent migration. The influence of metallic stent (MS) design characteristics, including axial force (AF), on the safety and efficacy of EUS‐HGS remains unclear. Methods: This multicenter retrospective study included patients with unresectable malignant biliary obstruction who underwent EUS‐HGS using either a high‐AF MS (Niti‐S biliary S‐type) or a low‐AF MS (EGIS biliary) between January 2019 and December 2022. Propensity score matching was performed in a 1:2 ratio. Outcomes included clinical success, early and late non‐recurrent biliary obstruction (non‐RBO) AEs, RBO, time to RBO (TRBO), and overall survival (OS). Results: After matching, 27 patients in the high‐AF group and 54 in the low‐AF group were analyzed. Clinical success, RBO rate, TRBO, OS, and late non‐RBO AE rates were similar between groups. However, early non‐RBO AEs were more frequent in the high‐AF group (37% vs. 13%, p = 0.02). Conclusions: Of the two partially covered MSs evaluated, the EGIS biliary stent demonstrated fewer early non‐RBO AEs after EUS‐HGS.
- 30 January 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 33 (6) , 472-479
Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy
Background: Neoadjuvant chemotherapy (NAC) with gemcitabine and S‐1 (GS) is the standard regimen for resectable pancreatic cancer (PC) in Japan. However, its efficacy in elderly patients and those with impaired renal function remains unclear. Methods: We retrospectively analyzed patients with resectable PC who received NAC GS. Patients were classified as elderly (≥ 75 years) or non‐elderly (< 75 years). The primary endpoint was relative dose intensity (RDI) of NAC. Secondary endpoints included adverse events (AEs), perioperative outcomes, RDI of adjuvant chemotherapy (AC), recurrence‐free survival (RFS), and overall survival (OS). Results: A total of 185 patients were included (non‐elderly: 148, elderly: 37). Median creatinine clearance (CCr) was lower in elderly patients (64.2 vs. 84.5 mL/min, p < 0.001). Mean RDI of GS was significantly lower in elderly patients and those with CCr < 50 mL/min, particularly when both factors coexisted. Severe hematologic AEs were more frequent in these groups, though perioperative outcomes were similar. While initiation of AC was delayed and RDI of adjuvant S‐1 was lower in elderly patients, RFS and OS did not significantly differ between groups. Conclusions: NAC GS appears feasible in elderly patients with resectable PC, though caution is needed in those with impaired renal function.
- 30 January 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 33 (6) , 472-479
Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy
Background: Neoadjuvant chemotherapy (NAC) with gemcitabine and S‐1 (GS) is the standard regimen for resectable pancreatic cancer (PC) in Japan. However, its efficacy in elderly patients and those with impaired renal function remains unclear. Methods: We retrospectively analyzed patients with resectable PC who received NAC GS. Patients were classified as elderly (≥ 75 years) or non‐elderly (< 75 years). The primary endpoint was relative dose intensity (RDI) of NAC. Secondary endpoints included adverse events (AEs), perioperative outcomes, RDI of adjuvant chemotherapy (AC), recurrence‐free survival (RFS), and overall survival (OS). Results: A total of 185 patients were included (non‐elderly: 148, elderly: 37). Median creatinine clearance (CCr) was lower in elderly patients (64.2 vs. 84.5 mL/min, p < 0.001). Mean RDI of GS was significantly lower in elderly patients and those with CCr < 50 mL/min, particularly when both factors coexisted. Severe hematologic AEs were more frequent in these groups, though perioperative outcomes were similar. While initiation of AC was delayed and RDI of adjuvant S‐1 was lower in elderly patients, RFS and OS did not significantly differ between groups. Conclusions: NAC GS appears feasible in elderly patients with resectable PC, though caution is needed in those with impaired renal function.
- 16 January 2026
- Published by S. Karger AG in Digestion
- p. 1-10
Gastrointestinal Bleeding after Particle Radiotherapy for Pancreatic Cancer
Introduction: Particle radiotherapy (PRT) is a new option for the treatment of unresectable pancreatic cancer (PC). While gastrointestinal bleeding (GIB) is a feared adverse event, real-world evidence in this setting is limited. Methods: We conducted a single-center retrospective study to evaluate the frequency and outcomes of GIB and to elucidate the risk factors for GIB after PRT for PC. Results: Thirty-four patients were included. Twenty-nine received PRT to the pancreatic primary, while five received PRT for metastases. Concurrent chemotherapy was given to 26 patients (76%). Eleven patients (32%) experienced acute GIB symptoms after PRT. Median time from PRT to GIB was 13.2 months. Endoscopic signs of hemorrhage were observed in 8 patients (24%), and endoscopic hemostasis was performed in six (18%). Three cases presented with ruptured pseudoaneurysms, of which two were treated with transarterial embolization. Hemostasis was ultimately achieved in all cases, and no deaths occurred directly as a result of GIB. However, overall survival after GIB was short (median: 1.9 months). Median overall survival after PRT tended to be longer in bleeders than in non-bleeders (26.8 vs. 22.7 months, p = 0.03). Concurrent chemotherapy was associated with a lower risk of GIB in univariate analysis (p = 0.05). Conclusion: GIB after PRT may not be as rare as previously believed, particularly in the terminal stages of PC.
- 16 January 2026
- Published by S. Karger AG in Digestion
- p. 1-10
Gastrointestinal Bleeding after Particle Radiotherapy for Pancreatic Cancer
Introduction: Particle radiotherapy (PRT) is a new option for the treatment of unresectable pancreatic cancer (PC). While gastrointestinal bleeding (GIB) is a feared adverse event, real-world evidence in this setting is limited. Methods: We conducted a single-center retrospective study to evaluate the frequency and outcomes of GIB and to elucidate the risk factors for GIB after PRT for PC. Results: Thirty-four patients were included. Twenty-nine received PRT to the pancreatic primary, while five received PRT for metastases. Concurrent chemotherapy was given to 26 patients (76%). Eleven patients (32%) experienced acute GIB symptoms after PRT. Median time from PRT to GIB was 13.2 months. Endoscopic signs of hemorrhage were observed in 8 patients (24%), and endoscopic hemostasis was performed in six (18%). Three cases presented with ruptured pseudoaneurysms, of which two were treated with transarterial embolization. Hemostasis was ultimately achieved in all cases, and no deaths occurred directly as a result of GIB. However, overall survival after GIB was short (median: 1.9 months). Median overall survival after PRT tended to be longer in bleeders than in non-bleeders (26.8 vs. 22.7 months, p = 0.03). Concurrent chemotherapy was associated with a lower risk of GIB in univariate analysis (p = 0.05). Conclusion: GIB after PRT may not be as rare as previously believed, particularly in the terminal stages of PC.
- 19 June 2025
- Published by Wiley in Hepatology Research
Progressive Sarcopenia as a Prognostic Marker in the Era of Immunotherapy
- 19 June 2025
- Published by Wiley in Hepatology Research
Progressive Sarcopenia as a Prognostic Marker in the Era of Immunotherapy
- 17 June 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (5) , 736-742
Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma
- 17 June 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (5) , 736-742
Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma
- 25 May 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (5) , 685-693
Bone loss, osteoporosis, and fractures in patients with resected pancreatic head cancer
- 25 May 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (5) , 685-693
Bone loss, osteoporosis, and fractures in patients with resected pancreatic head cancer
- 10 April 2025
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 18 (3) , 520-526
Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency
A 64-year-old man with a history of surgery for rectal cancer and colon cancer was referred for a hepatic mass identified on computed tomography (CT). He was diagnosed with unresectable intrahepatic cholangiocarcinoma (ICC) with perihilar and para-aortic lymph node metastases. After 4 cycles of gemcitabine and cisplatin combination therapy (GC therapy), follow-up CT showed slight enlargement of the primary tumor and a slight increase in carbohydrate antigen (CA) 19–9. Genetic testing was performed during GC therapy based on the strong family history of cancer. Germline pathogenic variant in MLH1 was identified, leading to the diagnosis of Lynch syndrome (LS) with mismatch repair deficiency (dMMR: loss of MLH1/PMS2). Durvalumab was added to GC therapy following regulatory approval in Japan. A significant reduction in tumor size and CA19-9 was observed after only two cycles of GC and durvalumab therapy. Continuous improvement was observed, and conversion surgery involving liver resection, partial inferior vena cava resection, and perihilar and para-aortic lymph nodes dissection was performed with curative intent. No malignant cells were found in any of the resected specimens, consistent with pathological complete response.
- 10 April 2025
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 18 (3) , 520-526
Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency
A 64-year-old man with a history of surgery for rectal cancer and colon cancer was referred for a hepatic mass identified on computed tomography (CT). He was diagnosed with unresectable intrahepatic cholangiocarcinoma (ICC) with perihilar and para-aortic lymph node metastases. After 4 cycles of gemcitabine and cisplatin combination therapy (GC therapy), follow-up CT showed slight enlargement of the primary tumor and a slight increase in carbohydrate antigen (CA) 19–9. Genetic testing was performed during GC therapy based on the strong family history of cancer. Germline pathogenic variant in MLH1 was identified, leading to the diagnosis of Lynch syndrome (LS) with mismatch repair deficiency (dMMR: loss of MLH1/PMS2). Durvalumab was added to GC therapy following regulatory approval in Japan. A significant reduction in tumor size and CA19-9 was observed after only two cycles of GC and durvalumab therapy. Continuous improvement was observed, and conversion surgery involving liver resection, partial inferior vena cava resection, and perihilar and para-aortic lymph nodes dissection was performed with curative intent. No malignant cells were found in any of the resected specimens, consistent with pathological complete response.
- 15 August 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 55 (4) , 1530-1540
Liver Oligometastasis in Biliary Tract Cancer and Impact on Survival Outcomes
Purpose Outcomes of unresectable biliary tract cancer (BTC) with varying extents of liver involvement remain unclear. We evaluated characteristics and outcomes of BTC patients with liver metastases who underwent chemotherapy. Methods We retrospectively reviewed consecutive BTC patients with synchronous or metachronous intrahepatic metastases who started first-line chemotherapy at our institution between January 2016 and December 2021. Results Ninety-six patients were included, of which 57 only had liver metastases and 39 had multiorgan involvement. The liver only group had longer median overall survival (OS) (11.8 vs. 7.4 months, P = 0.006) and median progression-free survival (PFS) (4.1 vs. 2.7 months, P = 0.035) than the multiorgan group. Patients with oligometastases (defined as no more than three liver metastases) achieved longer OS than those with polymetastases (four or more liver metastases) in the entire cohort. Within the liver only group, there were no significant differences in OS or PFS between the oligometastasis and polymetastasis groups. Patients who underwent subsequent surgery had significantly longer median OS than those who did not (44.4 vs. 7.7 months, P < 0.001). Age ≥ 75 years, liver-only metastasis, modified Glasgow prognostic score ≥ 1 carcinoembryonic antigen ≥ 5 μg/L, and subsequent surgery were independent predictors of OS. Liver oligometastasis was only a significant predictor of longer OS in univariate Cox analysis. Conclusions Outcomes in BTC patients with metastases limited to the liver, particularly those with oligometastasis, were more favorable than those with multiorgan metastases. Selected cases, generally with liver oligometastases, may achieve prolonged OS through subsequent surgery.
- 15 August 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 55 (4) , 1530-1540
Liver Oligometastasis in Biliary Tract Cancer and Impact on Survival Outcomes
Purpose Outcomes of unresectable biliary tract cancer (BTC) with varying extents of liver involvement remain unclear. We evaluated characteristics and outcomes of BTC patients with liver metastases who underwent chemotherapy. Methods We retrospectively reviewed consecutive BTC patients with synchronous or metachronous intrahepatic metastases who started first-line chemotherapy at our institution between January 2016 and December 2021. Results Ninety-six patients were included, of which 57 only had liver metastases and 39 had multiorgan involvement. The liver only group had longer median overall survival (OS) (11.8 vs. 7.4 months, P = 0.006) and median progression-free survival (PFS) (4.1 vs. 2.7 months, P = 0.035) than the multiorgan group. Patients with oligometastases (defined as no more than three liver metastases) achieved longer OS than those with polymetastases (four or more liver metastases) in the entire cohort. Within the liver only group, there were no significant differences in OS or PFS between the oligometastasis and polymetastasis groups. Patients who underwent subsequent surgery had significantly longer median OS than those who did not (44.4 vs. 7.7 months, P < 0.001). Age ≥ 75 years, liver-only metastasis, modified Glasgow prognostic score ≥ 1 carcinoembryonic antigen ≥ 5 μg/L, and subsequent surgery were independent predictors of OS. Liver oligometastasis was only a significant predictor of longer OS in univariate Cox analysis. Conclusions Outcomes in BTC patients with metastases limited to the liver, particularly those with oligometastasis, were more favorable than those with multiorgan metastases. Selected cases, generally with liver oligometastases, may achieve prolonged OS through subsequent surgery.
- Open Access
- 30 July 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (4) , 515-526
Outcomes of partially covered self-expandable metal stents with different uncovered lengths in endoscopic ultrasound-guided hepaticogastrostomy: a Japanese retrospective study
Background/Aims: The optimal length of the uncovered portion of partially covered self-expandable metal stents (PCSEMSs) used in endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) remains unclear. This study investigated the safety and efficacy of PCSEMSs with different uncovered lengths, with a focus on stent migration and time to recurrent biliary obstruction (RBO).Methods: Outcomes of patients undergoing EUS-HGS using PCSEMSs with 5-mm and 20-mm uncovered portions at our institution from January 2016 to December 2021 were compared.Results: Sixty-two patients underwent EUS-HGS using PCSEMS (5/20-mm uncovered portions: 32/30). Stent migration occurred only in the 5-mm group. There were no differences in RBO rates (28.1% vs. 40.0%) or median time to RBO (6.8 vs. 7.1 months) between the two groups. Median overall survival (OS) was longer in the 20-mm group (3.1 vs. 4.9 months, p=0.037) due to the higher number of patients that resumed chemotherapy after EUS-HGS (56.7% vs. 28.1%, p=0.029). Good performance status, absence of hepatic metastases, and chemotherapy after EUS-HGS were independent predictors of longer OS.Conclusions: No migration was observed in patients treated with PCSEMS with 20-mm uncovered portions. Patients treated with PCSEMS with 20-mm uncovered portions performed at least as well as those treated with 5-mm uncovered portions in all material respects.
- 30 July 2024
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 57 (4) , 515-526
Open AccessOutcomes of partially covered self-expandable metal stents with different uncovered lengths in endoscopic ultrasound-guided hepaticogastrostomy: a Japanese retrospective study
Background/Aims: The optimal length of the uncovered portion of partially covered self-expandable metal stents (PCSEMSs) used in endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) remains unclear. This study investigated the safety and efficacy of PCSEMSs with different uncovered lengths, with a focus on stent migration and time to recurrent biliary obstruction (RBO).Methods: Outcomes of patients undergoing EUS-HGS using PCSEMSs with 5-mm and 20-mm uncovered portions at our institution from January 2016 to December 2021 were compared.Results: Sixty-two patients underwent EUS-HGS using PCSEMS (5/20-mm uncovered portions: 32/30). Stent migration occurred only in the 5-mm group. There were no differences in RBO rates (28.1% vs. 40.0%) or median time to RBO (6.8 vs. 7.1 months) between the two groups. Median overall survival (OS) was longer in the 20-mm group (3.1 vs. 4.9 months, p=0.037) due to the higher number of patients that resumed chemotherapy after EUS-HGS (56.7% vs. 28.1%, p=0.029). Good performance status, absence of hepatic metastases, and chemotherapy after EUS-HGS were independent predictors of longer OS.Conclusions: No migration was observed in patients treated with PCSEMS with 20-mm uncovered portions. Patients treated with PCSEMS with 20-mm uncovered portions performed at least as well as those treated with 5-mm uncovered portions in all material respects.